Premature physiologic aging as a paradigm for understanding increased risk of adverse health across the lifespan of survivors of childhood cancer

Kirsten K. Ness, James L Kirkland, Maria Monica Gramatges, Zhaoming Wang, Mondira Kundu, Kelly McCastlain, Xiujie Li-Harms, Jinghui Zhang, Tamar Tchkonia, Saskia Martine Francesca Pluijm, Gregory T. Armstrong

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

The improvement in survival of childhood cancer observed across the past 50 years has resulted in a growing acknowledgment that simply extending the lifespan of survivors is not enough. It is incumbent on both the cancer research and the clinical care communities to also improve the health span of survivors. It is well established that aging adult survivors of childhood cancer are at increased risk of chronic health conditions, relative to the general population. However, as the first generation of survivors age into their 50s and 60s, it has become increasingly evident that this population is also at risk of early onset of physiologic aging. Geriatric measures have uncovered evidence of reduced strength and speed and increased fatigue, all components of frailty, among survivors with a median age of 33 years, which is similar to adults older than 65 years of age in the general population. Furthermore, frailty in survivors independently increased the risk of morbidity and mortality. Although there has been a paucity of research investigating the underlying biologic mechanisms for advanced physiologic age in survivors, results from geriatric populations suggest five biologically plausible mechanisms that may be potentiated by exposure to cancer therapies: increased cellular senescence, reduced telomere length, epigenetic modifications, somatic mutations, and mitochondrial DNA infidelity. There is now a critical need for research to elucidate the biologic mechanisms of premature aging in survivors of childhood cancer. This research could pave the way for new frontiers in the prevention of these life-changing outcomes.

Original languageEnglish (US)
Pages (from-to)2206-2215
Number of pages10
JournalJournal of Clinical Oncology
Volume36
Issue number21
DOIs
StatePublished - Jul 20 2018

Fingerprint

Premature Aging
Survivors
Health
Neoplasms
Research
Geriatrics
Population
Cell Aging
Telomere
Mitochondrial DNA
Epigenomics
Fatigue
Morbidity
Mutation
Survival
Mortality

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Premature physiologic aging as a paradigm for understanding increased risk of adverse health across the lifespan of survivors of childhood cancer. / Ness, Kirsten K.; Kirkland, James L; Monica Gramatges, Maria; Wang, Zhaoming; Kundu, Mondira; McCastlain, Kelly; Li-Harms, Xiujie; Zhang, Jinghui; Tchkonia, Tamar; Francesca Pluijm, Saskia Martine; Armstrong, Gregory T.

In: Journal of Clinical Oncology, Vol. 36, No. 21, 20.07.2018, p. 2206-2215.

Research output: Contribution to journalReview article

Ness, KK, Kirkland, JL, Monica Gramatges, M, Wang, Z, Kundu, M, McCastlain, K, Li-Harms, X, Zhang, J, Tchkonia, T, Francesca Pluijm, SM & Armstrong, GT 2018, 'Premature physiologic aging as a paradigm for understanding increased risk of adverse health across the lifespan of survivors of childhood cancer', Journal of Clinical Oncology, vol. 36, no. 21, pp. 2206-2215. https://doi.org/10.1200/JCO.2017.76.7467
Ness, Kirsten K. ; Kirkland, James L ; Monica Gramatges, Maria ; Wang, Zhaoming ; Kundu, Mondira ; McCastlain, Kelly ; Li-Harms, Xiujie ; Zhang, Jinghui ; Tchkonia, Tamar ; Francesca Pluijm, Saskia Martine ; Armstrong, Gregory T. / Premature physiologic aging as a paradigm for understanding increased risk of adverse health across the lifespan of survivors of childhood cancer. In: Journal of Clinical Oncology. 2018 ; Vol. 36, No. 21. pp. 2206-2215.
@article{163e567fafb34ce4afb72f4afd8594a8,
title = "Premature physiologic aging as a paradigm for understanding increased risk of adverse health across the lifespan of survivors of childhood cancer",
abstract = "The improvement in survival of childhood cancer observed across the past 50 years has resulted in a growing acknowledgment that simply extending the lifespan of survivors is not enough. It is incumbent on both the cancer research and the clinical care communities to also improve the health span of survivors. It is well established that aging adult survivors of childhood cancer are at increased risk of chronic health conditions, relative to the general population. However, as the first generation of survivors age into their 50s and 60s, it has become increasingly evident that this population is also at risk of early onset of physiologic aging. Geriatric measures have uncovered evidence of reduced strength and speed and increased fatigue, all components of frailty, among survivors with a median age of 33 years, which is similar to adults older than 65 years of age in the general population. Furthermore, frailty in survivors independently increased the risk of morbidity and mortality. Although there has been a paucity of research investigating the underlying biologic mechanisms for advanced physiologic age in survivors, results from geriatric populations suggest five biologically plausible mechanisms that may be potentiated by exposure to cancer therapies: increased cellular senescence, reduced telomere length, epigenetic modifications, somatic mutations, and mitochondrial DNA infidelity. There is now a critical need for research to elucidate the biologic mechanisms of premature aging in survivors of childhood cancer. This research could pave the way for new frontiers in the prevention of these life-changing outcomes.",
author = "Ness, {Kirsten K.} and Kirkland, {James L} and {Monica Gramatges}, Maria and Zhaoming Wang and Mondira Kundu and Kelly McCastlain and Xiujie Li-Harms and Jinghui Zhang and Tamar Tchkonia and {Francesca Pluijm}, {Saskia Martine} and Armstrong, {Gregory T.}",
year = "2018",
month = "7",
day = "20",
doi = "10.1200/JCO.2017.76.7467",
language = "English (US)",
volume = "36",
pages = "2206--2215",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "21",

}

TY - JOUR

T1 - Premature physiologic aging as a paradigm for understanding increased risk of adverse health across the lifespan of survivors of childhood cancer

AU - Ness, Kirsten K.

AU - Kirkland, James L

AU - Monica Gramatges, Maria

AU - Wang, Zhaoming

AU - Kundu, Mondira

AU - McCastlain, Kelly

AU - Li-Harms, Xiujie

AU - Zhang, Jinghui

AU - Tchkonia, Tamar

AU - Francesca Pluijm, Saskia Martine

AU - Armstrong, Gregory T.

PY - 2018/7/20

Y1 - 2018/7/20

N2 - The improvement in survival of childhood cancer observed across the past 50 years has resulted in a growing acknowledgment that simply extending the lifespan of survivors is not enough. It is incumbent on both the cancer research and the clinical care communities to also improve the health span of survivors. It is well established that aging adult survivors of childhood cancer are at increased risk of chronic health conditions, relative to the general population. However, as the first generation of survivors age into their 50s and 60s, it has become increasingly evident that this population is also at risk of early onset of physiologic aging. Geriatric measures have uncovered evidence of reduced strength and speed and increased fatigue, all components of frailty, among survivors with a median age of 33 years, which is similar to adults older than 65 years of age in the general population. Furthermore, frailty in survivors independently increased the risk of morbidity and mortality. Although there has been a paucity of research investigating the underlying biologic mechanisms for advanced physiologic age in survivors, results from geriatric populations suggest five biologically plausible mechanisms that may be potentiated by exposure to cancer therapies: increased cellular senescence, reduced telomere length, epigenetic modifications, somatic mutations, and mitochondrial DNA infidelity. There is now a critical need for research to elucidate the biologic mechanisms of premature aging in survivors of childhood cancer. This research could pave the way for new frontiers in the prevention of these life-changing outcomes.

AB - The improvement in survival of childhood cancer observed across the past 50 years has resulted in a growing acknowledgment that simply extending the lifespan of survivors is not enough. It is incumbent on both the cancer research and the clinical care communities to also improve the health span of survivors. It is well established that aging adult survivors of childhood cancer are at increased risk of chronic health conditions, relative to the general population. However, as the first generation of survivors age into their 50s and 60s, it has become increasingly evident that this population is also at risk of early onset of physiologic aging. Geriatric measures have uncovered evidence of reduced strength and speed and increased fatigue, all components of frailty, among survivors with a median age of 33 years, which is similar to adults older than 65 years of age in the general population. Furthermore, frailty in survivors independently increased the risk of morbidity and mortality. Although there has been a paucity of research investigating the underlying biologic mechanisms for advanced physiologic age in survivors, results from geriatric populations suggest five biologically plausible mechanisms that may be potentiated by exposure to cancer therapies: increased cellular senescence, reduced telomere length, epigenetic modifications, somatic mutations, and mitochondrial DNA infidelity. There is now a critical need for research to elucidate the biologic mechanisms of premature aging in survivors of childhood cancer. This research could pave the way for new frontiers in the prevention of these life-changing outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85050081161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050081161&partnerID=8YFLogxK

U2 - 10.1200/JCO.2017.76.7467

DO - 10.1200/JCO.2017.76.7467

M3 - Review article

C2 - 29874132

AN - SCOPUS:85050081161

VL - 36

SP - 2206

EP - 2215

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 21

ER -